OasisLMS

This course will be comprehensive AUA/SUO and NCCN Guidelines on APC in the management and outcomes of men with advanced, metastatic and CRPC. The course will include risk stratification, germline testing, PSMA PET imaging, the use of ADT in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed mHSPC. Early treatment intensification and evidenced based guidelines will be covered. This includes management of biochemical recurrence as well as metastatic disease. The course will also cover non-metastatic CRPC, and treatment for mCRPC as well. The use of sequencing, combination therapy, somatic testing and precision medicine with PARP inhibitors will also be discussed. The course will also cover emerging second and third line therapies for CRPC as well as sequencing.

ACKNOWLEDGEMENTS: 
Support provided by independent educational grants from: 

• Astellas
• Lantheus Medical Imaging
• Novartis Pharmaceuticals Corporation
• Pfizer, Inc

• Urologists 
• Residents
• APPs

At the conclusion of this activity, participants will be able to: 

1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing.
2. Describe appropriate use of treatment-related to specific genetic alterations.
3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC.
4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines.
5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines.

FACULTY DISCLOSURES 

Name	Company Name	Relationship Type	End Date
Cookson, Michael	Pfizer	Consultant or Advisor	Current
Jarrard, David F.	No relevant financial relationships to disclose
Kibel, Adam S.	Janssen	Scientific Study or Trial	Current
Scarpato, Kristen R.	CxBladder	Scientific Study or Trial	Current
	UroGen	Consultant or Advisor	Current

EDUCATION COUNCIL DISCLOSURES
Education Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

---

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.